ID

4281

Description

ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Link

http://clinicaltrials.gov/ct2/show/record/NCT00952588

Keywords

  1. 11/14/11 11/14/11 -
  2. 12/6/13 12/6/13 - Martin Dugas
  3. 4/11/14 4/11/14 - Julian Varghese
  4. 12/16/14 12/16/14 - Martin Dugas
Uploaded on

December 6, 2013

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Criteria NCT00952588

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion
Description

Inclusion

Provision of written informed consent
Description

consent

Data type

boolean

Newly diagnosed male or female patients aged 60 and over
Description

Age

Data type

boolean

De Novo or Secondary AML
Description

Diagnosis

Data type

boolean

Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age ?75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
Description

Other

Data type

boolean

Exclusion
Description

Exclusion

Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
Description

other trial

Data type

boolean

Administration of LDAC is clinically contraindicated
Description

Contraindication LDAC

Data type

boolean

Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
Description

M3

Data type

boolean

Patients with blast crisis of chronic myeloid leukaemia
Description

CML blast crisis

Data type

boolean

Medical concepts
Description

Medical concepts

Informed Consent
Description

Informed Consent

Data type

string

Alias
UMLS CUI
C0021430
Age
Description

Age

Data type

string

Alias
UMLS CUI
C0001779
SNOMED CT 2010_0731
102518004
Diagnosis
Description

Diagnosis

Data type

string

Alias
UMLS CUI
C0011900
SNOMED CT 2010_0731
439401001
Acute myeloic leukemia
Description

AML

Data type

string

Alias
UMLS CUI
C0023467
SNOMED CT 2010_0731
91861009
MedDRA 13.1
10000880
ICD-10-CM Version 2010
C92.0
ICD-9-CM Version 2011
205.0
WHO performance status finding
Description

WHO performance status finding

Data type

string

Alias
UMLS CUI
C1298651
SNOMED CT 2010_0731
373802001
Enrollment
Description

Enrollment

Data type

string

Alias
UMLS CUI
C1516879
Contraindication to medical treatment
Description

Contraindication to medical treatment

Data type

string

Alias
UMLS CUI
C0852648
MedDRA 13.1
10010833
Acute Promyelocytic Leukemia
Description

APL

Data type

string

Alias
UMLS CUI
C0023487
SNOMED CT 2010_0731
110004001
MedDRA 13.1
10001019
ICD-10-CM Version 2010
C92.4
Chronic myeloid leukemia
Description

CML

Data type

string

Alias
UMLS CUI
C0023473
SNOMED CT 2010_0731
63364005
MedDRA 13.1
10009700
ICD-10-CM Version 2010
C92.1
ICD-9-CM Version 2011
205.1
Blast phase
Description

Blast crisis

Data type

string

Alias
UMLS CUI
C0005699
SNOMED CT 2010_0731
278180008
MedDRA 13.1
10053747

Similar models

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion
consent
Item
Provision of written informed consent
boolean
Age
Item
Newly diagnosed male or female patients aged 60 and over
boolean
Diagnosis
Item
De Novo or Secondary AML
boolean
Other
Item
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age ?75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
boolean
Item Group
Exclusion
other trial
Item
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
boolean
Contraindication LDAC
Item
Administration of LDAC is clinically contraindicated
boolean
M3
Item
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
boolean
CML blast crisis
Item
Patients with blast crisis of chronic myeloid leukaemia
boolean
Item Group
Medical concepts
Informed Consent
Item
Informed Consent
string
C0021430 (UMLS CUI)
Age
Item
Age
string
C0001779 (UMLS CUI)
102518004 (SNOMED CT 2010_0731)
Diagnosis
Item
Diagnosis
string
C0011900 (UMLS CUI)
439401001 (SNOMED CT 2010_0731)
AML
Item
Acute myeloic leukemia
string
C0023467 (UMLS CUI)
91861009 (SNOMED CT 2010_0731)
10000880 (MedDRA 13.1)
C92.0 (ICD-10-CM Version 2010)
205.0 (ICD-9-CM Version 2011)
WHO performance status finding
Item
WHO performance status finding
string
C1298651 (UMLS CUI)
373802001 (SNOMED CT 2010_0731)
Enrollment
Item
Enrollment
string
C1516879 (UMLS CUI)
Contraindication to medical treatment
Item
Contraindication to medical treatment
string
C0852648 (UMLS CUI)
10010833 (MedDRA 13.1)
APL
Item
Acute Promyelocytic Leukemia
string
C0023487 (UMLS CUI)
110004001 (SNOMED CT 2010_0731)
10001019 (MedDRA 13.1)
C92.4 (ICD-10-CM Version 2010)
CML
Item
Chronic myeloid leukemia
string
C0023473 (UMLS CUI)
63364005 (SNOMED CT 2010_0731)
10009700 (MedDRA 13.1)
C92.1 (ICD-10-CM Version 2010)
205.1 (ICD-9-CM Version 2011)
Blast crisis
Item
Blast phase
string
C0005699 (UMLS CUI)
278180008 (SNOMED CT 2010_0731)
10053747 (MedDRA 13.1)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial